5kng: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='5kng' size='340' side='right'caption='[[5kng]], [[Resolution|resolution]] 1.35Å' scene=''> | <StructureSection load='5kng' size='340' side='right'caption='[[5kng]], [[Resolution|resolution]] 1.35Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5kng]] is a 4 chain structure with sequence from [ | <table><tr><td colspan='2'>[[5kng]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5KNG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5KNG FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.35Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5kng FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5kng OCA], [https://pdbe.org/5kng PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5kng RCSB], [https://www.ebi.ac.uk/pdbsum/5kng PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5kng ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 22: | Line 22: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Synthetic construct | [[Category: Synthetic construct]] | ||
[[Category: Gilliland | [[Category: Gilliland G]] | ||
[[Category: Malia | [[Category: Malia T]] | ||
[[Category: Obmolova | [[Category: Obmolova G]] | ||
[[Category: Teplyakov | [[Category: Teplyakov A]] | ||
Latest revision as of 13:04, 27 September 2023
CRYSTAL STRUCTURE OF ANTI-IL-13 DARPIN 6G9CRYSTAL STRUCTURE OF ANTI-IL-13 DARPIN 6G9
Structural highlights
Publication Abstract from PubMedDesigned ankyrin repeat proteins (DARPin(R)) are artificial non-immunoglobulin binding proteins with potential applications as therapeutic molecules. DARPin 6G9 binds interleukin-13 with high affinity and blocks the signaling pathway and as such is promising for the treatment of asthma and other atopic diseases. The crystal structures of DARPin 6G9 in the unbound form and in complex with IL-13 were determined at high resolution. The DARPin competes for the same epitope as the IL-13 receptor chain 13Ralpha1 but does not interfere with the binding of the other receptor chain, IL-4Ralpha. Analysis of multiple copies of the DARPin molecule in the crystal indicates the conformational instability in the N-terminal cap that was predicted from molecular dynamics simulations. Comparison of the DARPin structures in the free state and in complex with IL-13 reveals a concerted movement of the ankyrin repeats upon binding resulted in the opening of the binding site. The induced-fit mode of binding employed by DARPin 6G9 is very unusual for DARPins since they were designed as particularly stable and rigid molecules. This finding shows that DARPins can operate by various binding mechanisms and suggests that some flexibility in the scaffold may be an advantage. Conformational flexibility of an anti-IL-13 DARPindagger.,Teplyakov A, Malia TJ, Obmolova G, Jacobs SA, O'Neil KT, Gilliland GL Protein Eng Des Sel. 2016 Nov 23. PMID:27881684[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||